Ansofaxine

Ansofaxine hydrochloride (INN) (former developmental code names LY03005, LPM570065), also known as 4-methylbenzoate desvenlafaxine hydrochloride, is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) which is under development by Luye Pharma Group for the treatment of major depressive disorder (MDD).[1][2][3][4] It is described as an SNDRI and prodrug to desvenlafaxine.[2] However, unlike desvenlafaxine, which has in vitro IC50 values of 53 nM and 538 nM for inhibition of serotonin and norepinephrine reuptake, respectively, ansofaxine has respective in vitro IC50 values of 723 nM, 763 nM, and 491 nM for serotonin, norepinephrine, and dopamine reuptake inhibition.[2] As of July 2018, the drug is in preregistration for MDD in the United States, the European Union, Japan, and China.[1]

Ansofaxine
Clinical data
Other namesLY03005; LPM570065; 4-Methylbenzoate desvenlafaxine hydrochloride
Routes of
administration		By mouth
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC24H31NO3
Molar mass381.516 g·mol−1
3D model (JSmol)

See also

References
  1. http://adisinsight.springer.com/drugs/800039935
  2. Zhang R, Li X, Shi Y, Shao Y, Sun K, Wang A, Sun F, Liu W, Wang D, Jin J, Li Y (2014). "The effects of LPM570065, a novel triple reuptake inhibitor, on extracellular serotonin, dopamine and norepinephrine levels in rats". PLOS ONE. 9 (3): e91775. doi:10.1371/journal.pone.0091775. PMC 3948889. PMID 24614602.
  3. Dale, Elena; Bang-Andersen, Benny; Sánchez, Connie (2015). "Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs". Biochemical Pharmacology. 95 (2): 81–97. doi:10.1016/j.bcp.2015.03.011. ISSN 0006-2952. PMID 25813654.
  4. Completion of Phase 1 Clinical Studies of Ansofaxine Hydrochloride Extended Release Tablets (LY03005) in the U.S.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.